Payment overview · 2025
General Payments
$195,384.36
307 reported records · 22 companies
Healthcare provider profile · identity verified
Abdul Ali Abdellatif, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · WEBSTER, TX · NPI 1164560595
Verified facts
What the public records show
CMS Open Payments records show Abdul Ali Abdellatif, M.D. received $195,384.36 in general payments during 2025 across 307 reported records.
Mallinckrodt Hospital Products Inc. accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Krystexxa, Linzess, Ozempic, Rayaldee.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Auryxia by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Krystexxa by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rayaldee by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $71,039.63 | 36.4% | 63 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47,663.56 | 24.4% | 92 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29,831.51 | 15.3% | 41 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20,504.45 | 10.5% | 37 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14,963.54 | 7.7% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $5,433.45 | 2.8% | 18 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $5,030.54 | 2.6% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $193.29 | 0.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $176.26 | 0.1% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $149.59 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.41 | 0.1% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.62 | 0.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.85 | 0.0% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $29.40 | 0.0% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $29.01 | 0.0% | 1 | 2025 |
| Veloxis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.86 | 0.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.33 | 0.0% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $24.69 | 0.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.94 | 0.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.05 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.62 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.76 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,836.00 | 35 |
| Consulting Fee | $39,282.00 | 14 |
| Travel and Lodging | $24,339.50 | 117 |
| Honoraria | $13,200.00 | 4 |
| Compensation for serving as faculty or as a speaker for a medical education program | $9,600.00 | 4 |
| Food and Beverage | $6,126.86 | 133 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $71,039.63 | 63 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $39,590.60 | 75 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29,776.23 | 37 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $20,504.45 | 37 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $14,963.54 | 19 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $5,433.45 | 18 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $5,151.96 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $193.29 | 8 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $149.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $89.41 | 5 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $55.28 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $51.62 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| ENVARSUS Normalized: envarsus |
Drug | Veloxis Pharmaceuticals, Inc. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 31 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 288 | 94 |
| Carvedilol | Carvedilol | 271 | 87 |
| Allopurinol | Allopurinol | 224 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 197 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 42 |
| Calcitriol | Calcitriol | 141 | 50 |
| Losartan Potassium | Losartan Potassium | 139 | 43 |
| Prednisone | Prednisone | 135 | 40 |
| Nifedipine Er | Nifedipine | 129 | 42 |
| Farxiga | Dapagliflozin Propanediol | 116 | 31 |
| Gabapentin | Gabapentin | 106 | 35 |
| Sevelamer Carbonate | Sevelamer Carbonate | 100 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 26 |
| Prosol | Parenteral Amino Acid 20% No.1 | 85 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 27 |
| Valsartan | Valsartan | 83 | 30 |
| Clonidine Hcl | Clonidine Hcl | 81 | 23 |
| Lisinopril | Lisinopril | 77 | 26 |
| Bumetanide | Bumetanide | 71 | 23 |
| Xphozah | Tenapanor Hcl | 69 | 18 |
| Cinacalcet Hcl | Cinacalcet Hcl | 65 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 25 |
| Omeprazole | Omeprazole | 64 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 24 |
| Azithromycin | Azithromycin | 54 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 18 |
| Mirtazapine | Mirtazapine | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 11 |
| Ozempic | Semaglutide | 51 | 11 |
| Colchicine | Colchicine | 47 | 24 |
| Midodrine Hcl | Midodrine Hcl | 47 | 20 |
| Spironolactone | Spironolactone | 45 | 14 |
| Cefdinir | Cefdinir | 44 | 39 |
| Retacrit | Epoetin Alfa-Epbx | 44 | 12 |
| Clinisol | Parenteral Amino Acid 15% No.5 | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 23 |
| Eliquis | Apixaban | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 12 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 38 | 14 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Finasteride | Finasteride | 37 | 16 |
| Metolazone | Metolazone | 37 | 16 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 35 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 11 |
| Cephalexin | Cephalexin | 33 | suppressed |
| Rayaldee | Calcifediol | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Calcium Acetate | Calcium Acetate | 31 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Auryxia | Ferric Citrate | 29 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | suppressed |
| Procrit | Epoetin Alfa | 29 | 13 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | 11 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 18 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Lactulose | Lactulose | 19 | 14 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Edarbi | Azilsartan Medoxomil | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lupkynis | Voclosporin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Krystexxa | Pegloticase | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $195,384.36 · 307 records | Mallinckrodt Hospital Products Inc. | ACTHAR, BENLYSTA, CREON, CRYSVITA, ENVARSUS, FARXIGA, FUROSCIX, Fabhalta, Filspari, IBSRELA, INSPIRE, ISTURISA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LINZESS, Ozempic, PURIFIED CORTROPHIN GEL, RAYALDEE, Rybelsus, TAVNEOS, Vafseo, Vanrafia, Wegovy, Yorvipath | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error